pethidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analgesics, pethidine derivatives and other synthetic small molecule miu-opioid receptor agonists	1690	57-42-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: meperidine pethidine isonipecaine meperidol pethanol pethidin meperidine hydrochloride pethidine hydrochloride meperidine HCl pethidine HCl	A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. Molecular weight: 247.34 Formula: C15H21NO2 CLOGP: 2.23 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 29.54 ALOGS: -2.35 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

meperidine
pethidine
isonipecaine
meperidol
pethanol
pethidin
meperidine hydrochloride
pethidine hydrochloride
meperidine HCl
pethidine HCl

A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.

Molecular weight: 247.34
Formula: C15H21NO2
CLOGP: 2.23
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 29.54
ALOGS: -2.35
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
0.40	g	P
0.40	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	3.22 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	13 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	60.65 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	52 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.42 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 10, 1942	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4510.87	15.10	2005	15512	308682	63162823
Contrast media allergy	407.67	15.10	101	17416	2300	63469205
International normalised ratio fluctuation	292.34	15.10	78	17439	2400	63469105
Myoglobin urine present	228.68	15.10	51	17466	721	63470784
Bloody discharge	222.36	15.10	57	17460	1494	63470011
Drug intolerance	216.33	15.10	339	17178	308322	63163183
Upper respiratory tract infection	202.11	15.10	173	17344	81874	63389631
Psoriasis	183.56	15.10	168	17349	86789	63384716
Obliterative bronchiolitis	169.20	15.10	49	17468	2046	63469459
Lyme disease	169.17	15.10	55	17462	3394	63468111
Serotonin syndrome	146.75	15.10	94	17423	28588	63442917
Amylase increased	139.90	15.10	56	17461	6289	63465216
Toxic encephalopathy	124.35	15.10	52	17465	6527	63464978
Temperature regulation disorder	110.99	15.10	47	17470	6085	63465420
Troponin increased	102.93	15.10	52	17465	10069	63461436
Treatment failure	96.32	15.10	186	17331	198857	63272648
Vomiting	92.77	15.10	351	17166	559266	62912239
Food allergy	91.51	15.10	50	17467	11351	63460154
Herpes zoster	89.49	15.10	112	17405	82350	63389155
Coeliac disease	75.67	15.10	46	17471	12751	63458754
Blood potassium increased	74.36	15.10	52	17465	18257	63453248
Blood lactate dehydrogenase increased	69.94	15.10	55	17462	23061	63448444
Rheumatoid arthritis	66.11	15.10	186	17331	253633	63217872
Immunodeficiency	65.21	15.10	50	17467	20204	63451301
Thrombocytopenia	62.03	15.10	132	17385	151025	63320480
Nausea	61.65	15.10	424	17093	854047	62617458
Alopecia	61.01	15.10	10	17507	337526	63133979
Hypertension	57.98	15.10	189	17328	279114	63192391
Blood creatine phosphokinase increased	56.84	15.10	55	17462	30375	63441130
Foetal death	56.17	15.10	36	17481	10944	63460561
Bronchitis chronic	52.11	15.10	25	17492	4328	63467177
Urticaria	50.68	15.10	129	17388	165673	63305832
Condition aggravated	46.01	15.10	27	17490	402190	63069315
Infusion related reaction	45.50	15.10	160	17357	245361	63226144
Rash erythematous	43.33	15.10	56	17461	42454	63429051
Rash	41.84	15.10	281	17236	560590	62910915
Hallucination	40.66	15.10	62	17455	54755	63416750
Bursitis	38.07	15.10	49	17468	36992	63434513
Respiratory arrest	36.43	15.10	45	17472	32600	63438905
Pemphigus	34.17	15.10	5	17512	183721	63287784
Wound	33.97	15.10	3	17514	163260	63308245
Anaphylactic reaction	33.39	15.10	63	17454	66037	63405468
Therapeutic product effect incomplete	32.83	15.10	92	17425	124964	63346541
Hyperhidrosis	30.96	15.10	82	17435	107754	63363751
Iron deficiency	30.44	15.10	21	17496	7209	63464296
Prescribed overdose	28.74	15.10	41	17476	34112	63437393
Neonatal respiratory depression	28.20	15.10	6	17511	67	63471438
Fluid retention	27.84	15.10	55	17462	59631	63411874
Systemic lupus erythematosus	26.87	15.10	12	17505	208906	63262599
Hand deformity	26.08	15.10	6	17511	159451	63312054
Diarrhoea	25.72	15.10	106	17411	715260	62756245
Arteriospasm coronary	25.36	15.10	15	17502	3953	63467552
Synovitis	25.22	15.10	10	17507	186908	63284597
Product dose omission issue	25.01	15.10	17	17500	234296	63237209
Neonatal seizure	24.28	15.10	8	17509	514	63470991
Moaning	24.11	15.10	9	17508	837	63470668
Extremity contracture	23.75	15.10	10	17507	1275	63470230
Joint swelling	23.64	15.10	163	17354	327503	63144002
Pulse absent	23.55	15.10	16	17501	5358	63466147
Product use in unapproved indication	23.48	15.10	10	17507	179070	63292435
Cardiac aneurysm	23.18	15.10	9	17508	931	63470574
Limb mass	22.73	15.10	13	17504	3219	63468286
Discomfort	22.50	15.10	9	17508	167365	63304140
Pancreatic carcinoma recurrent	21.18	15.10	5	17512	92	63471413
Nervous system disorder	21.15	15.10	26	17491	18740	63452765
Death	21	15.10	45	17472	374336	63097169
Skin reaction	20.79	15.10	23	17494	14826	63456679
Alanine aminotransferase increased	20.37	15.10	69	17448	103701	63367804
Asthma	20.13	15.10	79	17438	127482	63344023
General physical health deterioration	19.69	15.10	16	17501	201386	63270119
Weight increased	19.55	15.10	26	17491	260766	63210739
Respiratory alkalosis	19.36	15.10	11	17506	2690	63468815
Staphylococcal infection	19.21	15.10	38	17479	41218	63430287
Peripheral swelling	18.46	15.10	28	17489	265914	63205591
Nasopharyngitis	18.40	15.10	26	17491	254231	63217274
Asthenia	17.69	15.10	51	17466	383553	63087952
Disease progression	17.51	15.10	6	17511	122752	63348753
Blister	17.41	15.10	7	17510	129807	63341698
Dactylitis	17.03	15.10	10	17507	2602	63468903
Dyspnoea	16.95	15.10	110	17407	661203	62810302
Weight decreased	16.59	15.10	32	17485	276766	63194739
Acute kidney injury	16.19	15.10	30	17487	263385	63208120
Breath sounds absent	16.05	15.10	5	17512	268	63471237
Anti-cyclic citrullinated peptide antibody positive	16.03	15.10	6	17511	116206	63355299
Arthropod bite	15.99	15.10	15	17502	7963	63463542
Back pain	15.94	15.10	126	17391	264019	63207486
Injection site pain	15.84	15.10	8	17509	129792	63341713
Neutropenia	15.78	15.10	15	17502	174990	63296515
Encephalopathy neonatal	15.62	15.10	3	17514	19	63471486
Intentional product misuse	15.17	15.10	44	17473	60873	63410632

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	523.70	16.19	267	6194	80262	34870208
Nightmare	171.83	16.19	73	6388	14318	34936152
Sedation	157.32	16.19	77	6384	20929	34929541
Nephrolithiasis	130.74	16.19	77	6384	30256	34920214
Product used for unknown indication	108.27	16.19	27	6434	956	34949514
Hyperhidrosis	93.85	16.19	91	6370	75601	34874869
Chills	61.07	16.19	75	6386	80968	34869502
Nausea	54.09	16.19	161	6300	339747	34610723
Mucosal atrophy	29.91	16.19	6	6455	76	34950394
Serotonin syndrome	28.53	16.19	26	6435	19907	34930563
Oesophageal mucosa erythema	28.26	16.19	5	6456	30	34950440
Drug dependence	27.86	16.19	28	6433	24189	34926281
Facial wasting	26.02	16.19	6	6455	151	34950319
Motor developmental delay	25.50	16.19	8	6453	660	34949810
Postoperative delirium	24.73	16.19	6	6455	189	34950281
Haemorrhoids thrombosed	24.40	16.19	6	6455	200	34950270
Carditis	24.29	16.19	6	6455	204	34950266
Pseudopolyp	23.62	16.19	6	6455	229	34950241
Bone infarction	22.99	16.19	6	6455	255	34950215
Administration related reaction	22.88	16.19	5	6456	98	34950372
Drug abuser	22.32	16.19	12	6449	3942	34946528
Starvation	22.20	16.19	6	6455	292	34950178
Cytokine release syndrome	21.93	16.19	24	6437	22853	34927617
Gastrointestinal tract irritation	21.82	16.19	6	6455	312	34950158
Blood albumin abnormal	21.71	16.19	6	6455	318	34950152
Intra-abdominal haemorrhage	21.59	16.19	10	6451	2394	34948076
Restrictive cardiomyopathy	20.92	16.19	7	6454	708	34949762
Gastrointestinal scarring	19.96	16.19	5	6456	180	34950290
Anal stenosis	19.65	16.19	5	6456	192	34950278
Respiratory arrest	19.55	16.19	25	6436	28018	34922452
Large intestinal stenosis	18.84	16.19	8	6453	1559	34948911
Ileal perforation	16.62	16.19	6	6455	760	34949710
Oedema mucosal	16.44	16.19	6	6455	785	34949685

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4395.78	14.50	1894	17974	297022	79427498
Contrast media allergy	332.93	14.50	85	19783	2437	79722083
International normalised ratio fluctuation	279.07	14.50	79	19789	3375	79721145
Bloody discharge	210.32	14.50	56	19812	1897	79722623
Myoglobin urine present	202.12	14.50	47	19821	900	79723620
Lyme disease	176.25	14.50	55	19813	3295	79721225
Upper respiratory tract infection	169.69	14.50	157	19711	91011	79633509
Drug intolerance	158.50	14.50	256	19612	263863	79460657
Serotonin syndrome	152.59	14.50	110	19758	44917	79679603
Psoriasis	150.91	14.50	146	19722	89441	79635079
Obliterative bronchiolitis	148.01	14.50	47	19821	2981	79721539
Amylase increased	111.78	14.50	55	19813	11154	79713366
Temperature regulation disorder	100.64	14.50	42	19826	5811	79718709
Nightmare	94.09	14.50	66	19802	25795	79698725
Toxic encephalopathy	93.28	14.50	49	19819	11391	79713129
Nausea	92.90	14.50	476	19392	956720	78767800
Vomiting	88.93	14.50	364	19504	665464	79059056
Food allergy	84.40	14.50	45	19823	10779	79713741
Hyperhidrosis	84.17	14.50	142	19726	151350	79573170
Product used for unknown indication	83.95	14.50	26	19842	1518	79723002
Infusion related reaction	76.79	14.50	174	19694	230063	79494457
Troponin increased	74.40	14.50	51	19817	19204	79705316
Coeliac disease	74.19	14.50	42	19826	11309	79713211
Nephrolithiasis	68.23	14.50	75	19793	53216	79671304
Herpes zoster	63.70	14.50	96	19772	92987	79631533
Treatment failure	62.64	14.50	134	19734	170352	79554168
Rheumatoid arthritis	62.34	14.50	151	19717	208319	79516201
Sedation	59.56	14.50	69	19799	51826	79672694
Urticaria	58.44	14.50	137	19731	185064	79539456
Foetal death	55.93	14.50	31	19837	8013	79716507
Immunodeficiency	55.68	14.50	45	19823	21723	79702797
Blood potassium increased	55.53	14.50	51	19817	29224	79695296
Hypertension	53.89	14.50	193	19675	330799	79393721
Bronchitis chronic	47.71	14.50	23	19845	4459	79720061
Blood lactate dehydrogenase increased	41.49	14.50	50	19818	39120	79685400
Rash	40.31	14.50	264	19604	578094	79146426
Chills	38.53	14.50	107	19761	160127	79564393
Respiratory arrest	37.44	14.50	58	19810	57492	79667028
Bursitis	36.74	14.50	45	19823	35799	79688721
Thrombocytopenia	33.61	14.50	143	19725	265116	79459404
Rash erythematous	33.17	14.50	55	19813	57714	79666806
Condition aggravated	32.09	14.50	47	19821	501077	79223443
Death	30.85	14.50	59	19809	566455	79158065
Alopecia	30.18	14.50	10	19858	231345	79493175
Therapeutic product effect incomplete	29.62	14.50	90	19778	141555	79582965
Drug abuser	28.26	14.50	18	19850	5995	79718525
Joint swelling	26.65	14.50	142	19726	288504	79436016
Blood creatine phosphokinase increased	26.64	14.50	54	19814	66036	79658484
General physical health deterioration	26.56	14.50	18	19850	275220	79449300
Hallucination	26.54	14.50	63	19805	85682	79638838
Pain	25.73	14.50	278	19590	703524	79020996
Cytokine release syndrome	24.42	14.50	37	19831	35961	79688559
Prescribed overdose	24.39	14.50	38	19830	37845	79686675
Disease progression	23.99	14.50	8	19860	184354	79540166
Iron deficiency	23.05	14.50	20	19848	10634	79713886
Moaning	22.41	14.50	9	19859	1128	79723392
Extremity contracture	21.86	14.50	10	19858	1722	79722798
Anaphylactic reaction	21.18	14.50	57	19811	83686	79640834
Neutropenia	20.40	14.50	25	19843	287685	79436835
Product dose omission issue	20.35	14.50	19	19849	247518	79477002
Limb mass	20.03	14.50	12	19856	3587	79720933
Cardiac aneurysm	19.91	14.50	9	19859	1509	79723011
Postoperative delirium	19.26	14.50	6	19862	357	79724163
Discomfort	19.09	14.50	4	19864	125613	79598907
Exposure during pregnancy	19.06	14.50	62	19806	101070	79623450
Pancreatic carcinoma recurrent	18.43	14.50	5	19863	182	79724338
Fluid retention	18.14	14.50	48	19820	69761	79654759
Synovitis	17.21	14.50	8	19860	150726	79573794
Administration related reaction	17.17	14.50	5	19863	236	79724284
Infection	17.16	14.50	111	19757	241601	79482919
Pyrexia	17.01	14.50	250	19618	678459	79046061
Diarrhoea	16.65	14.50	140	19728	880349	78844171
Restrictive cardiomyopathy	16.55	14.50	7	19861	1001	79723519
Emotional distress	16.51	14.50	33	19835	39936	79684584
Breath sounds absent	16.22	14.50	5	19863	287	79724233
Respiratory depression	15.45	14.50	26	19842	27604	79696916
Drug dependence	14.89	14.50	32	19836	40737	79683783
Acute kidney injury	14.70	14.50	73	19795	519331	79205189

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02AB02	NERVOUS SYSTEM ANALGESICS OPIOIDS Phenylpiperidine derivatives
ATC	N02AB52	NERVOUS SYSTEM ANALGESICS OPIOIDS Phenylpiperidine derivatives
ATC	N02AB72	NERVOUS SYSTEM ANALGESICS OPIOIDS Phenylpiperidine derivatives
ATC	N02AG03	NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with antispasmodics
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000700	Analgesics
MeSH PA	D000701	Analgesics, Opioid
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D009294	Narcotics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35482	narcotic analgesic
CHEBI has role	CHEBI:53784	antispasmodics
CHEBI has role	CHEBI:55322	mu-opioid agonists
CHEBI has role	CHEBI:59282	kappa-opioid receptor agonists
FDA MoA	N0000175684	Full Opioid Agonists
FDA EPC	N0000175690	Opioid Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pain	indication	22253000
General anesthesia	indication	50697003
Severe pain	indication	76948002
Labor pain	indication	247412007
Local anesthesia	indication	386761002
Sedation as Adjunct to Anesthesia	indication
Dependent drug abuse	contraindication	6525002
Necrosis	contraindication	6574001
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Agranulocytosis	contraindication	17182001	DOID:12987
Jaundice	contraindication	18165001
Lowered convulsive threshold	contraindication	19260006
Disorder of the central nervous system	contraindication	23853001	DOID:331
Alcohol intoxication	contraindication	25702006
Gangrene	contraindication	36024000
Hypothyroidism	contraindication	40930008	DOID:1459
Myxedema	contraindication	43153006	DOID:11634
Low blood pressure	contraindication	45007003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Thrombophlebitis	contraindication	64156001	DOID:3875
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Poisoning by acetaminophen	contraindication	70273001
Sleep apnea	contraindication	73430006	DOID:0050847
Extrapyramidal disease	contraindication	76349003
Urethral stricture	contraindication	76618002
Decreased respiratory function	contraindication	80954004
Disorder of brain	contraindication	81308009	DOID:936
Injury of head	contraindication	82271004
Chronic idiopathic constipation	contraindication	82934008
Cor pulmonale	contraindication	83291003	DOID:8515
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Gastrointestinal obstruction	contraindication	126765001
Hb SS disease	contraindication	127040003	DOID:10923
Seizure disorder	contraindication	128613002
Drug-induced psychosis	contraindication	191483003	DOID:1742
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Pheochromocytoma	contraindication	302835009
Bone marrow depression	contraindication	307762000
Coma	contraindication	371632003
Primary adrenocortical insufficiency	contraindication	373662000
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Breastfeeding (mother)	contraindication	413712001
Central nervous system depression	contraindication	418072004
Acute exacerbation of asthma	contraindication	708038006
Injection Site Sequelae	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.56	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	AGONIST	Ki	6.04	CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.49	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN				WOMBAT-PK
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.63	WOMBAT-PK
Glutamate receptor ionotropic, NMDA 3A	Ion channel	Q8TCU5	NMD3A_HUMAN				WOMBAT-PK
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.65	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	6.39	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	4.75	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_CAVPO		Ki	6.35	CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRM_RAT OPRK_RAT SGMR1_RAT		EC50	6.15	CHEMBL
Opioid receptor	GPCR		SGMR1_MOUSE OPRD_MOUSE OPRK_MOUSE OPRM_MOUSE		IC50	6.30	CHEMBL

External reference:

ID	Source
4019813	VUID
N0000147902	NUI
D01383	KEGG_DRUG
50-13-5	SECONDARY_CAS_RN
4018030	VANDF
4019813	VANDF
C0025376	UMLSCUI
CHEBI:6754	CHEBI
CHEMBL1701	ChEMBL_ID
CHEMBL607	ChEMBL_ID
DB00454	DRUGBANK_ID
4058	PUBCHEM_CID
7221	IUPHAR_LIGAND_ID
103755	RXNORM
1858	MMSL
5046	MMSL
d00017	MMSL
001542	NDDF
004620	NDDF
2878005	SNOMEDCT_US
387298007	SNOMEDCT_US
54544005	SNOMEDCT_US
D008614	MESH_DESCRIPTOR_UI
411	INN_ID
9E338QE28F	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3545	SOLUTION	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3545	SOLUTION	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3545	SOLUTION	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4595	TABLET	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4595	TABLET	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4595	TABLET	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4596	TABLET	100 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4596	TABLET	100 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4596	TABLET	100 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8595	TABLET	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8595	TABLET	50 mg	ORAL	ANDA	32 sections
Meperidine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8595	TABLET	50 mg	ORAL	ANDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1176	INJECTION, SOLUTION	25 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1176	INJECTION, SOLUTION	25 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1176	INJECTION, SOLUTION	25 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1178	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1178	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1178	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1179	INJECTION, SOLUTION	75 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1179	INJECTION, SOLUTION	75 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1179	INJECTION, SOLUTION	75 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1180	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1180	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1180	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1181	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1181	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1181	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1201	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1201	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	32 sections
DEMEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1203	INJECTION, SOLUTION	25 mg	INTRAMUSCULAR	NDA	32 sections